The market does not need much of an excuse to punish a stock, and yesterday GlaxoSmithKline gave it just that. The British drugmaker announced that the final trials of a new asthma medication showed that the drug, Relovair, is no better than Advair (also known as Seretide), a similar GSK medication already on the market. Relovair’s main advantage is that patients need only take it once a day, as opposed to Advair’s twice-a-day dose.
市場不需要太多借口來懲罰一只股票，而葛蘭素史克(GlaxoSmithKline, GSK)周一提供了充足理由。這家英國制藥商宣布，最新哮喘藥物Relovair的最終試驗表明，新藥效果并未超越GSK目前銷售的哮喘藥Advair——又名舒利迭(Seretide)。Relovair的主要優點是患者只需每天服藥一次，而Advair的劑量是一天兩次。
您已閱讀25%（607字），剩余75%（1836字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。